电阻抗断层成像引导呼气末正压滴定对中重度急性呼吸窘迫综合征患者预后的影响:多中心随机对照试验研究方案
本研究为前瞻性、多中心、单盲、平行组、适应性设计的随机对照试验,拟纳入诊断后72小时内的中重度急性呼吸窘迫综合征成人患者376例,比较电阻抗断层成像引导的呼气末正压滴定与低吸入氧浓度-呼气末正压表对28天死亡率的影响,主要结局为28天死亡率,预计干预组28天死亡率降低15%。
要点
- 电阻抗断层成像引导呼气末正压滴定可能平衡肺过度膨胀与塌陷,但对其临床结局的影响尚不明确。
- 试验拟纳入376例中重度急性呼吸窘迫综合征患者,主要结局为28天死亡率。
- 样本量基于干预组28天死亡率降低15%估算,纳入188例时进行中期分析以重新评估样本量并评估无效性。
核心结论
- 电阻抗断层成像引导的呼气末正压滴定对中重度急性呼吸窘迫综合征患者临床结局的影响尚不明确,本试验旨在比较其与低吸入氧浓度-呼气末正压表的效果。
研究设计与样本
- 前瞻性、多中心、单盲、平行组、适应性设计的随机对照试验,采用意向性治疗分析。
- 拟纳入诊断后72小时内的中重度急性呼吸窘迫综合征成人患者376例。
- 干预组接受电阻抗断层成像引导的递减式呼气末正压滴定,对照组根据低吸入氧浓度-呼气末正压表选择呼气末正压,其他呼吸机参数按ARDSNet策略设置。
- 随访至入组后28天;纳入188例时进行中期分析以重新评估样本量和评估无效性。
主要发现
- 主要结局为28天死亡率。
- 次要结局包括28天无呼吸机天数和无休克天数、重症监护病房和住院时间、成功脱机率、需要补救治疗的比例、并发症、呼吸变量和序贯器官衰竭评估评分。
- 样本量基于干预组28天死亡率降低15%估算。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Electrical impedance tomography (EIT)-guided positive end-expiratory pressure (PEEP) titration can achieve the compromise between lung overdistension and collapse which may minimize ventilator-induced lung injury in these patients. However, the effect of EIT-guided PEEP titration on the clinical outcomes remains unknown. The objective of this trial is to investigate the effects of EIT-guided PEEP titration on the clinical outcomes for moderate or severe ARDS, compared to the low fraction of inspired oxygen (FiO2)-PEEP table. METHODS: This is a prospective, multicenter, single-blind, parallel-group, adaptive designed, randomized controlled trial (RCT) with intention-to-treat analysis. Adult patients with moderate to severe ARDS less than 72 h after diagnosis will be included in this study. Participants in the intervention group will receive PEEP titrated by EIT with a stepwise decrease PEEP trial, whereas participants in the control group will select PEEP based on the low FiO2-PEEP table. Other ventilator parameters will be set according to the ARDSNet strategy. Participants will be followed up until 28 days after enrollment. Three hundred seventy-six participants will be recruited based on a 15% decrease of 28-day mortality in the intervention group, with an interim analysis for sample size re-estimation and futility assessment being undertaken once 188 participants have been recruited. The primary outcome is 28-day mortality. The secondary outcomes include ventilator-free days and shock-free days at day 28, length of ICU and hospital stay, the rate of successful weaning, proportion requiring rescue therapies, compilations, respiratory variables, and Sequential Organ Failure Assessment (SOFA). DISCUSSION: As a heterogeneous syndrome, ARDS has different responses to treatment and further results in different clinical outcomes. PEEP selection will depend on the properties of patients and can be individually achieved by EIT. This study will be the largest randomized trial to investigate thoroughly the effect of individual PEEP titrated by EIT in moderate to severe ARDS patients to date. TRIAL REGISTRATION: ClinicalTrial.gov NCT05207202. First published on January 26, 2022.
引用
- Yuan X, Zhang R, Wang Y, et al. Effect of EIT-guided PEEP titration on prognosis of patients with moderate to severe ARDS: study protocol for a multicenter randomized controlled trial. Trials. 2023. PMID: 37041561. doi:10.1186/s13063-023-07280-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。